The circulating tumor cells market size has grown rapidly in recent years. It will grow from $13.27 billion in 2025 to $14.99 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to increasing cancer incidence rates, expansion of oncology research programs, growing use of blood-based diagnostics, rising adoption of minimally invasive testing methods, availability of advanced laboratory technologies.
The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $23.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of personalized oncology diagnostics, rising investments in cancer biomarker research, expansion of automated cell capture technologies, growing demand for early-stage cancer detection tools, increasing integration of ai in oncology diagnostics. Major trends in the forecast period include increasing use of liquid biopsy techniques, rising adoption of microfluidic ctc isolation devices, growing integration of automated ctc analysis systems, expansion of oncology research applications, enhanced focus on early cancer detection.
The increasing prevalence of cancer is anticipated to drive the expansion of the circulating tumor cells market in the coming years. Cancer is a condition in which certain cells in the body multiply uncontrollably and spread to other organs or tissues. Circulating tumor cells are utilized for the early identification and diagnosis of cancer, and as cancer incidence continues to rise, the demand for these technologies is growing accordingly. For example, in February 2024, according to the World Health Organization, a Switzerland-based international body focused on global health policy and public health initiatives, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared with the estimated 20 million cases reported in 2022. As a result, the rising burden of cancer is contributing significantly to the growth of the circulating tumor cells market.
Leading companies operating in the circulating tumor cells (CTC) space are increasingly concentrating on the development of advanced solutions, such as biomarker-specific CTC assays, to address the growing need for accurate, non-invasive cancer diagnostics and improved personalized treatment monitoring. These biomarker-specific assays allow for the detection and detailed characterization of circulating tumor cells based on particular protein expressions, providing richer phenotypic insights than conventional CTC enumeration techniques that largely deliver only total cell counts. For instance, in July 2023, Menarini Silicon Biosystems S.p.A., an Italy-based diagnostics firm, launched the CELLSEARCH CTC test incorporating the DLL3 biomarker as a Research Use Only service across North America and Europe. Built on the FDA-cleared CELLSEARCH platform, the assay is designed to identify circulating tumor cells expressing DLL3, a protein commonly overexpressed in aggressive small-cell lung cancer and neuroendocrine tumors. By targeting DLL3, the test supports phenotypic profiling of CTCs linked to poor prognosis, thereby aiding biopharmaceutical research focused on targeted therapy development. This advancement offers researchers a non-invasive approach to investigate tumor heterogeneity, track disease progression, and assess responses to precision treatments.
In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in cell analysis and offer advanced solutions for both research and clinical applications. Fluxion Biosciences, also based in the US, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).
Major companies operating in the circulating tumor cells market are BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., ScreenCell SAS, Aviva Biosciences Corporation, LungLife AI Inc., Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd., Bio-Techne Corporation, Qiagen N.V., STEMCELL Technologies Inc., Sysmex Corporation, Miltenyi Biotec GmbH, Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Agilent Technologies Inc.
North America was the largest region in the circulating tumor cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the circulating tumor cells market by increasing costs of imported microfluidic devices, imaging systems, reagents, and automated cell capture equipment. Oncology research centers and diagnostic laboratories in North America and Europe are most affected due to reliance on specialized imported instruments, while Asia-Pacific faces higher manufacturing input costs. These tariffs are raising test costs and slowing technology adoption. However, they are also encouraging domestic device development, localized reagent production, and regional innovation in liquid biopsy platforms.
The circulating tumor cells market research report is one of a series of new reports that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Circulating tumor cells (CTCs) represent solid tumor-derived cells that have detached from the primary tumor and entered the bloodstream, providing valuable diagnostic and prognostic information for cancer.
The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.
The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $23.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of personalized oncology diagnostics, rising investments in cancer biomarker research, expansion of automated cell capture technologies, growing demand for early-stage cancer detection tools, increasing integration of ai in oncology diagnostics. Major trends in the forecast period include increasing use of liquid biopsy techniques, rising adoption of microfluidic ctc isolation devices, growing integration of automated ctc analysis systems, expansion of oncology research applications, enhanced focus on early cancer detection.
The increasing prevalence of cancer is anticipated to drive the expansion of the circulating tumor cells market in the coming years. Cancer is a condition in which certain cells in the body multiply uncontrollably and spread to other organs or tissues. Circulating tumor cells are utilized for the early identification and diagnosis of cancer, and as cancer incidence continues to rise, the demand for these technologies is growing accordingly. For example, in February 2024, according to the World Health Organization, a Switzerland-based international body focused on global health policy and public health initiatives, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared with the estimated 20 million cases reported in 2022. As a result, the rising burden of cancer is contributing significantly to the growth of the circulating tumor cells market.
Leading companies operating in the circulating tumor cells (CTC) space are increasingly concentrating on the development of advanced solutions, such as biomarker-specific CTC assays, to address the growing need for accurate, non-invasive cancer diagnostics and improved personalized treatment monitoring. These biomarker-specific assays allow for the detection and detailed characterization of circulating tumor cells based on particular protein expressions, providing richer phenotypic insights than conventional CTC enumeration techniques that largely deliver only total cell counts. For instance, in July 2023, Menarini Silicon Biosystems S.p.A., an Italy-based diagnostics firm, launched the CELLSEARCH CTC test incorporating the DLL3 biomarker as a Research Use Only service across North America and Europe. Built on the FDA-cleared CELLSEARCH platform, the assay is designed to identify circulating tumor cells expressing DLL3, a protein commonly overexpressed in aggressive small-cell lung cancer and neuroendocrine tumors. By targeting DLL3, the test supports phenotypic profiling of CTCs linked to poor prognosis, thereby aiding biopharmaceutical research focused on targeted therapy development. This advancement offers researchers a non-invasive approach to investigate tumor heterogeneity, track disease progression, and assess responses to precision treatments.
In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in cell analysis and offer advanced solutions for both research and clinical applications. Fluxion Biosciences, also based in the US, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).
Major companies operating in the circulating tumor cells market are BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., ScreenCell SAS, Aviva Biosciences Corporation, LungLife AI Inc., Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd., Bio-Techne Corporation, Qiagen N.V., STEMCELL Technologies Inc., Sysmex Corporation, Miltenyi Biotec GmbH, Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Agilent Technologies Inc.
North America was the largest region in the circulating tumor cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the circulating tumor cells market by increasing costs of imported microfluidic devices, imaging systems, reagents, and automated cell capture equipment. Oncology research centers and diagnostic laboratories in North America and Europe are most affected due to reliance on specialized imported instruments, while Asia-Pacific faces higher manufacturing input costs. These tariffs are raising test costs and slowing technology adoption. However, they are also encouraging domestic device development, localized reagent production, and regional innovation in liquid biopsy platforms.
The circulating tumor cells market research report is one of a series of new reports that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Circulating tumor cells (CTCs) represent solid tumor-derived cells that have detached from the primary tumor and entered the bloodstream, providing valuable diagnostic and prognostic information for cancer.
The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.
The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Circulating Tumor Cells Market Characteristics
3. Circulating Tumor Cells Market Supply Chain Analysis
4. Global Circulating Tumor Cells Market Trends and Strategies
5. Circulating Tumor Cells Market Analysis of End Use Industries
7. Global Circulating Tumor Cells Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Circulating Tumor Cells Total Addressable Market (TAM) Analysis for the Market
9. Circulating Tumor Cells Market Segmentation
10. Circulating Tumor Cells Market Regional and Country Analysis
11. Asia-Pacific Circulating Tumor Cells Market
12. China Circulating Tumor Cells Market
13. India Circulating Tumor Cells Market
14. Japan Circulating Tumor Cells Market
15. Australia Circulating Tumor Cells Market
16. Indonesia Circulating Tumor Cells Market
17. South Korea Circulating Tumor Cells Market
18. Taiwan Circulating Tumor Cells Market
19. South East Asia Circulating Tumor Cells Market
20. Western Europe Circulating Tumor Cells Market
21. UK Circulating Tumor Cells Market
22. Germany Circulating Tumor Cells Market
23. France Circulating Tumor Cells Market
24. Italy Circulating Tumor Cells Market
25. Spain Circulating Tumor Cells Market
26. Eastern Europe Circulating Tumor Cells Market
27. Russia Circulating Tumor Cells Market
28. North America Circulating Tumor Cells Market
29. USA Circulating Tumor Cells Market
30. Canada Circulating Tumor Cells Market
31. South America Circulating Tumor Cells Market
32. Brazil Circulating Tumor Cells Market
33. Middle East Circulating Tumor Cells Market
34. Africa Circulating Tumor Cells Market
36. Circulating Tumor Cells Market Competitive Landscape and Company Profiles
37. Circulating Tumor Cells Market Other Major and Innovative Companies
40. Circulating Tumor Cells Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Circulating Tumor Cells Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses circulating tumor cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for circulating tumor cells? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The circulating tumor cells market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Kits And Reagents; Blood Collection Tubes; Devices Or Systems2) By Technology: CTC Enrichment; CTC Detection; CTC Analysis
3) By Application: Clinical Or Liquid Biopsy; Research
Subsegments:
1) By Kits And Reagents: Cell Enrichment Kits; Detection Kits; Nucleic Acid Isolation Kits2) By Blood Collection Tubes: Standard Blood Collection Tubes; Specialized Blood Collection Tubes
3) By Devices Or Systems: Microfluidic Devices; Automated Cell Capture Systems; Imaging Systems
Companies Mentioned: BIOCEPT Inc.; Creativ MicroTech Inc.; Fluxion Biosciences Inc.; Ikonisys Inc.; ScreenCell SAS; Aviva Biosciences Corporation; LungLife AI Inc.; Menarini Silicon Biosystems S.p.A.; Canopus Bioscience Ltd.; IVDiagnostics Inc.; BioFluidica Inc.; Biolidics Limited; Rarecells Diagnostics SAS; Cynvenio Biosystems Inc.; ApoCell Inc.; Clearbridge BioMedics Pte. Ltd.; Celsee Inc.; RareCyte Inc.; On-chip Biotechnologies Co. Ltd.; Bio-Techne Corporation; Qiagen N.V.; STEMCELL Technologies Inc.; Sysmex Corporation; Miltenyi Biotec GmbH; Thermo Fisher Scientific Inc.; Greiner Bio-One International GmbH; Agilent Technologies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Circulating Tumor Cells market report include:- BIOCEPT Inc.
- Creativ MicroTech Inc.
- Fluxion Biosciences Inc.
- Ikonisys Inc.
- ScreenCell SAS
- Aviva Biosciences Corporation
- LungLife AI Inc.
- Menarini Silicon Biosystems S.p.A.
- Canopus Bioscience Ltd.
- IVDiagnostics Inc.
- BioFluidica Inc.
- Biolidics Limited
- Rarecells Diagnostics SAS
- Cynvenio Biosystems Inc.
- ApoCell Inc.
- Clearbridge BioMedics Pte. Ltd.
- Celsee Inc.
- RareCyte Inc.
- On-chip Biotechnologies Co. Ltd.
- Bio-Techne Corporation
- Qiagen N.V.
- STEMCELL Technologies Inc.
- Sysmex Corporation
- Miltenyi Biotec GmbH
- Thermo Fisher Scientific Inc.
- Greiner Bio-One International GmbH
- Agilent Technologies Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 14.99 Billion |
| Forecasted Market Value ( USD | $ 23.88 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
